ATE329264T1 - Nachweis von produkten von apoptosis - Google Patents

Nachweis von produkten von apoptosis

Info

Publication number
ATE329264T1
ATE329264T1 AT99910360T AT99910360T ATE329264T1 AT E329264 T1 ATE329264 T1 AT E329264T1 AT 99910360 T AT99910360 T AT 99910360T AT 99910360 T AT99910360 T AT 99910360T AT E329264 T1 ATE329264 T1 AT E329264T1
Authority
AT
Austria
Prior art keywords
therapy
patients
effectiveness
tumour
present
Prior art date
Application number
AT99910360T
Other languages
English (en)
Inventor
Stefan Holdenrieder
Martin Busch
Heinz Bodenmueller
Georg Fertig
Andreas Schalhorn
Petra Stieber
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19811739A external-priority patent/DE19811739A1/de
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Application granted granted Critical
Publication of ATE329264T1 publication Critical patent/ATE329264T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Holo Graphy (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
AT99910360T 1998-03-18 1999-03-18 Nachweis von produkten von apoptosis ATE329264T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19811739A DE19811739A1 (de) 1998-03-18 1998-03-18 Verlaufskontrolle der Radio- oder Chemotherapie bei Tumorpatienten durch die Detektion apaptotischer Produkte
US7949498P 1998-03-26 1998-03-26

Publications (1)

Publication Number Publication Date
ATE329264T1 true ATE329264T1 (de) 2006-06-15

Family

ID=26044710

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99910360T ATE329264T1 (de) 1998-03-18 1999-03-18 Nachweis von produkten von apoptosis

Country Status (7)

Country Link
US (1) US7759071B2 (de)
EP (1) EP1064549B1 (de)
JP (1) JP3517642B2 (de)
AT (1) ATE329264T1 (de)
AU (1) AU2934299A (de)
ES (1) ES2265682T3 (de)
WO (1) WO1999047924A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1483415A4 (de) * 2002-02-20 2006-02-01 Univ Virginia Nichtinvasiver diagnostischer test unter verwendung histonmodifizierter marker
GB0319376D0 (en) * 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
GB201012662D0 (en) * 2010-07-28 2010-09-15 Valirx Plc Method for detecting the presence of a gynaecological growth
GB201115099D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
AU2012349855B2 (en) * 2011-12-07 2017-12-07 Belgian Volition Sprl Method for detecting nucleosome adducts
EP2775304A1 (de) * 2013-03-07 2014-09-10 Universitätsspital Basel Verfahren zum Nachweis einer entzündlichen Störung

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500432A (en) 1990-08-01 1996-03-19 The Scripps Research Institute Induction and inhibition of apoptosis
JP3190042B2 (ja) * 1991-10-31 2001-07-16 マトリテク インコーポレイテッド 核マトリックス蛋白液アッセー
DE4318402A1 (de) * 1993-06-03 1994-12-08 Boehringer Mannheim Gmbh Verfahren zum Nachweis eines programmierten oder induzierten Zelltods eukaryontischer Zeller
DE4319506A1 (de) * 1993-06-12 1994-12-15 Boehringer Mannheim Gmbh Verfahren zum Nachweis metabolisch markierter DNA
US5750360A (en) * 1995-06-07 1998-05-12 Lxr Biotechnology Inc. Method for quantitatively measuring apoptosis
JP3392626B2 (ja) * 1996-02-21 2003-03-31 カネボウ株式会社 育毛剤の評価方法
DE69739909D1 (de) * 1996-03-26 2010-07-29 Michael S Kopreski Methoden aus plasma oder serum extrahierte extrazelluraere rna zur diagnoseüberwachung oder evaluation von krebs verwenden
WO1998034118A1 (en) * 1997-01-30 1998-08-06 Yale University Diagnostic methods and compositions based on the distribution of rad51
JP3688436B2 (ja) * 1997-07-08 2005-08-31 株式会社カネボウ化粧品 育毛剤の評価方法
US7229772B1 (en) * 1998-03-18 2007-06-12 Roche Diagnostics Gmbh Detection of apoptotic products

Also Published As

Publication number Publication date
AU2934299A (en) 1999-10-11
JP3517642B2 (ja) 2004-04-12
WO1999047924A1 (en) 1999-09-23
US20080108094A1 (en) 2008-05-08
US7759071B2 (en) 2010-07-20
EP1064549A1 (de) 2001-01-03
EP1064549B1 (de) 2006-06-07
JP2002507722A (ja) 2002-03-12
ES2265682T3 (es) 2007-02-16

Similar Documents

Publication Publication Date Title
ATE442592T1 (de) Detektion und/oder beobachtung von synuclein- assoziierten krankheiten
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
BRPI0213786B8 (pt) peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
ATE527016T1 (de) System zur überwachung oder behandlung von erkrankungen des nervensystems
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
DE69735436D1 (de) Methode zum nachweis von zell-apoptose
ATE411018T1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
ATE356994T1 (de) Screeningverfahren mit pim1-kinase oder pim3- kinase
ATE329264T1 (de) Nachweis von produkten von apoptosis
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
MX2014000204A (es) Metodo de administracion y tratamiento.
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
ATE142499T1 (de) Verwendung von kreatinphosphat oder phosphoenolbrenztraubensäure zur behandlung von tumoren
DE60016405D1 (de) Neurodegenerative-erkrankung verwandtes gen
CY1107921T1 (el) Μεθοδος για την προγνωση της αθροιστικης επιβιωσης ασθενων
ATE537823T1 (de) Verfahren zur behandlung von präeklampsie beim menschen mit resibufagenin
ES530592A0 (es) Procedimiento para la inactivacion de sustancias que provocan reacciones de incompatibilidad en productos sanguineos
ATE283478T1 (de) Verfahren und vorrichtung zur bestimmung des transformationspotentials von verbindungen.
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
EA199800821A1 (ru) Способ лечения аутизма
MX2021011015A (es) Tratamiento de la hiperglucemia con inhibidores del miembro 5 de la familia 39 de los transportadores de solutos (slc39a5).
WO2003028536A3 (en) Methods for diagnosing and treating heart disease

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1064549

Country of ref document: EP